Stock Details
REGN is Regeneron Pharmaceuticals, Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 649.42$. Average daily volumn in 3 months 704.64k. Market cap 78.74B



Stock symbol : REGN. Exchange : NasdaqGS. Currency : USD
Lastest price : 722.37$. Total volume : 650.86k. Market state POST
Click reload if you want to check the lastest price on market!!!

Regeneron Pharmaceuticals, Inc. (REGN)
Last Price
722.37$
Change
-9.49
Volume
650.86k

Previous Close731.86
Open731.66
Day Range720.14-732.69
Bid701.00 x 900
Ask722.27 x 800
Volume650.86k
Average Volume704.64k
Market Cap78.74B
Beta0.17
52 Week Range538.01-754.67
Trailing P/E14.73
Foward P/E16.65
Dividend (Yield %)N/A
Ex-Dividend DateN/A



Financial Details


According to Regeneron Pharmaceuticals, Inc.'s financial reports the company's revenue in 2021 were 16.07B an decrease( +100%) over the years 2020 revenue that were of 8.5B. In 2021 the company's total earnings were 8.08B while total earnings in 2020 were 3.51B( +166.67%).


Loading ...



Organization

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vei... n occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Market Cap:
78.74B
Revenue:
16.07B
Total Assets:
25.43B
Total Cash:
2.89B


News about "Regeneron Pharmaceuticals, Inc."

Regeneron Pharmaceuticals (NASDAQ: REGN)

Source from : The Motley Fool - 2 days ago

The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.See details»


Will Loss of REGEN-COV Sales Hurt Regeneron (REGN) in 2022?

Source from : Nasdaq - 3 days ago

Biotech giant Regeneron Pharmaceuticals REGN witnessed a massive surge in sales in 2021, driven by an exemplary contribution from REGEN-COV, a cocktail of two monoclonal antibodies — casirivimab and ...See details»


regeneron-pharmaceuticals-nasdaqregn-price-target-increased-to-97000-by-analysts-at-the-goldman-sachs-group-image

Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Increased to $970.00 by Analysts at The Goldman Sachs Group

Source from : Defense World - 3 days ago

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) had its price objective raised by The Goldman Sachs Group from $796.00 to $970.00 in a research note released on Monday, Stock Target Advisor ...See details»


Regeneron (REGN) Recently Broke Out Above the 20-Day Moving Average

Source from : YAHOO!Finance - 3 days ago

Regeneron (REGN) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, REGN crossed above the 20-day moving average, suggesting a ...See details»


REGN Regeneron Pharmaceuticals, Inc.

Source from : Seeking Alpha - 8 days ago

**NM signifies a non meaningful value. A dash signifies the data is not available.See details»


Insiders who sold Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) earlier year may find some solace in the 4.1% drop

Source from : Yahoo - 10 days ago

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) stock price has dropped 4.1% in the previous week, but insiders who sold US$16m in stock over the past year have had less luck. Given that the ...See details»


regeneron-pharmaceuticals-whale-trades-for-october-03-image

Regeneron Pharmaceuticals Whale Trades For October 03

Source from : Benzinga on MSN - 4 days ago

Someone with a lot of money to spend has taken a bearish stance on Regeneron Pharmaceuticals (NASDAQ:REGN). And retail traders should know. We noticed this today when the big position showed up on ...See details»


sequoia-financial-advisors-llc-trims-stock-position-in-regeneron-pharmaceuticals-inc-nasdaqregn-image

Sequoia Financial Advisors LLC Trims Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Source from : Defense World - 1 days ago

Sequoia Financial Advisors LLC lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 3.4% in the 2nd quarter, according to its most recent 13F filing with the ...See details»


Regeneron Elects Dr. Craig B. Thompson to Board of Directors

Source from : YAHOO!Finance - 4 days ago

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Craig B. Thompson, M.D., has been elected to the Board of Directors, effective immediately. Dr. Thompson has also been appointed to ...See details»


If You Invested $1000 in Regeneron 10 Years Ago, This Is How Much You'd Have Now

Source from : Zacks.com on MSN - 3 days ago

For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and ...See details»


Regeneron Pharmaceuticals (NASDAQ:REGN) stock performs better than its underlying earnings growth over last three years

Source from : Yahoo! Sports - 23 days ago

To wit, the Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) share price has flown 143% in the last three years. How nice for those who held the stock! It's also good to see the share price up 25% ...See details»


Aflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO

Source from : Business Insider - 7 days ago

30, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentations of positive detailed results from two pivotal trials investigating novel aflibercept ...See details»


10-best-pharmaceutical-stocks-to-buy-according-to-steven-boyds-armistice-capital-image

10 Best Pharmaceutical Stocks to Buy According to Steven Boyd’s Armistice Capital

Source from : Yahoo Finance - 11 hours ago

In this article, we will take a look at some of the notable pharma stocks to buy according to Steven Boyd’s Armistice Capital. To skip our analysis of Steven Boyd’s profile, investment strategy, and ...See details»


Regeneron : FDA Approves Dupixent For Prurigo Nodularis Treatment

Source from : Nasdaq - 9 days ago

(RTTNews) - The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis, Regeneron Pharmaceuticals Inc. (REGN) and Sanofi ...See details»